Crigler-Najjar (CN) disease is classified into two subtypes, type I and II. The molecular basis for the difference between these types is not well understood.
Introduction
Crigler-Najjar disease (CN) ' is a form of familial hyperbilirubinemia characterized by high serum levels of unconjugated syltransferase; CN, Crigler-Najjar disease; DOPC, dioleoyl phosphatidylcholine; UGTJ, human UGT1 gene.
bilirubin (1) . The disease is caused by an absence or strong reduction of the activity of the hepatic enzyme bilirubin UDPglucuronosyltransferase (B-UGT) (EC 2.4.1.17) . The CN syndrome can be divided into two subtypes; the more severe type I with high levels of serum bilirubin and the milder type II with lower levels of serum bilirubin and a reduction of these levels of more than 30% upon phenobarbital treatment (2) (3) (4) (5) (6) (7) (8) (9) (10) . Bile of type II patients contains bilirubin glucuronides, though much less than bile of healthy controls (2) (3) (4) .
Recently the human UGTI gene has been characterized at the molecular level (11) . At least four different transcripts are generated from a single gene by a mechanism of altemative splicing. This mechanism produces isoforms of UGT with transferase activity towards bilirubin and phenolic substrates. All UGTJ gene products share an identical carboxyl terminal domain. This constant domain probably contains the UDP-glucuronic acid binding site and the putative transmembrane helix. Mutations located in this constant part of the UGTI locus will affect all isoenzymes. The UGTI gene products have an unique amino terminal domain, termed exons UGTIA to UGTIF, which are responsible for the substrate specificity (11, 12) . Two UGT isoforms (B-UGTI and B-UGT2, the products of the UGTIA and UGTID exons) have been postulated to mediate bilirubin glucuronidating activity (11) .
To investigate the molecular basis for the difference between CN type I and II we identified mutations in the variable and the constant part of the bilirubin UGTI gene of CN type I and II patients (13) (14) (15) and expressed these mutant enzymes in COS cells.
Methods

Patients
Two CN type II patients and six CN type I patients were studied. Clinical features of these patients are described below and are summarized in Table I . Mutations present in these patients are described in Table I . CN type II patients. Patient A was diagnosed as a type II and described in reference 15. The patient is a 40-yr-old male. 1 mo after birth his serum bilirubin level was 85 ,qM, 3 was collected at an age of 5 wk. The bile was analyzed using HPLC. Unconjugated and conjugated bilirubin were detected, the composition was 5% bilirubin diconjugate, 30% bilirubin mono conjugate and 65% unconjugated bilirubin. Total bilirubin concentration in the sample, which contained -50% bile, was 36 uM.
The patient was treated with phenobarbital at an age of I yr, which resulted in a moderate response. When a dose of 5 mg/kg body wt was given for 1 wk serum bilirubin dropped from 120 to 87 ,uM. A week after the treatment was halted serum bilirubin was 92 yM.
At an age of 4 yr the patient receives 4 h of light therapy per d with 12 20-W tubes, with this treatment serum bilirubin levels range between 100 and 130 yM. Since her serum bilirubin is kept at a relatively low level with only limited treatment and because a significant amount of bilirubin glucuronides were detected in bile she was classified as type II, despite the limited phenobarbital response.
CN type I patients. Patient C at the age of 16, underwent an orthotopic liver transplantation. Before transplantation bilirubin levels were around 400 MuM and she did not respond to phenobarbital treatment (13) . A liver specimen did not contain detectable B-UGT activity (16) .
Patients D and E both underwent orthotopic liver transplantation (14) . Diagnosis of CN type I was based on high serum bilirubin levels, 460 MM in patient D and 430 uM in patient E. There was no response to phenobarbital treatment. Bile of patient E did not contain detectable amounts of bilirubin conjugates. Liver specimens did not contain any detectable B-UGT activity.
A clinical and immunological description of patients F and G was given (16), where these patients were termed C and D, respectively. Both patients underwent orthotopic liver transplantation. Patient F was a 3-yr-old (at the time of study) female with an average serum bilirubin of 430 MM. Patient G was a 9-yr-old (at the time of study) female with an average serum bilirubin of 420 ,uM. Liver specimens of both patients did not contain detectable B-UGT activity. Diagnosis of CN type I was based on high serum bilirubin levels and lack of phenobarbital response.
Patient H is a 16-yr-old boy in whom jaundice was noted soon after birth. On phototherapy, serum bilirubin levels varied from 340 to 425 MM. At the age of 15, he started experiencing difficulty in learning and had subtle motor abnormalities. There was no response to phenobarbital. He underwent orthotopic liver transplantation, which reversed the neurological abnormalities. Hepatic B-UGT activity was undetectable.
Chemicals DOPC was obtained from Avanti Polar Lipids, Inc. (Birmingham, AL). UDP-glucuronic acid and Triton X-100 from Boehringer (Mannheim, Germany). Bilirubin and cell dissociation solution from Sigma Chemical Co. (St Louis, MO). Nitro blue tetrazolium, 5-bromo, 4-chloro, 3- indoyl phosphate, acrylamide, bis acrylamide, goat anti-mouse alkaline phosphatase, goat anti-rabbit alkaline phosphatase, and goat antimouse peroxidase from Biorad (Veenendaal, The Netherlands). pSVK3 and DEAE dextran were from Pharmacia (Uppsala, Sweden). Nitrocellulose membranes 0.45 ,m pore size from Schleicher and Schuell (Dassel, Germany). 3', 3', 5', 5' Tetramethylbenzidine was from Fluka Chemie AG (Buchs Switzerland). Cromspher 5, C18, 100 x 10 mm, reverse phase column was from Chrompack (Middelburg, The Netherlands). Slide Write plus 5, from Advanced Graphics Software, Inc. (Carlsbad, CA).
All other chemicals were of analytical grade and obtained from E. Merck (Darmstadt, Germany).
Identification of mutations, site directed mutagenesis, and expression of recombinant B-UGT cDNAs in COS cells
Identification of mutations was performed as described previously (13) (14) (15) . B-UGTI cDNAs were cloned in the EcoRI and Apal restriction sites of pSVK3. Site-directed mutagenesis was performed as described in ( 17) . Plasmids were isolated using Qiagen and sequenced completely to confirm the introduction of the mutations and to exclude abnormalities.
COS cells were transfected using DEAE dextran. Cells grown in 162-cm2 culture bottles were incubated 4 h at 37°C in a 10% CO2 atmosphere with 9 ml optimum medium containing 2 mg/ml DEAE dextran, 100 MiM chloroquine, and 10 Mig of plasmid DNA. The medium was removed and the cells were treated for 2.5 min with 10% DMSO in PBS. The cells were washed twice with DME and grown for 2-3 d in DME containing 10% fetal calf serum. Cells were harvested using cell dissociation solution and washed twice with 5 mM Mops pH 7.0, 250 mM mannitol, and 2 mM EGTA. The cells were incubated for 15 min at 4°C in this buffer and disrupted with 25 strokes of a dounce. Nuclei and large debris were removed by centrifugation for 5 min at 7,000 g. The microsomal fraction was pelleted by centrifuging for 1 h at 100,000 g. COS cell microsomes were resuspended in 50 mM Hepes pH 7.8, 2 mM EDTA, and 20% glycerol (buffer A) and stored at -20°C.
Human liver microsomes were isolated as described (18), resuspended in buffer A and stored at -70°C.
Quantitation of B-UGT expression
Microtiter plates were coated overnight with the monoclonal antibody WPI (18) diluted 1:4000 in PBS. The plates were blocked with 1% bovine serum albumin in PBS for 2 h at 37°C. Different UGT containing preparations were solubilized with 1% Triton X-100 in deionized water for 1 h at 4°C, diluted 10 times with 0.1% Triton X-100, 1% BSA in PBS (buffer B), and applied to the microtiter plate for further dilution. Microsomal samples were diluted 20-320 times in buffer B, all samples were applied in triplicate. Standard immunopurified UGT was processed in the same way except that twofold dilutions from 20 to 20,960 times were used.
Binding was allowed to proceed for 2 h at 37°C. The plate was washed with PBS containing 0.05% Tween 20. As secondary antibody a polyclonal serum raised against immunopurified human UGT (16) was used. The serum was diluted 1:500 in PBS 0.1% Triton X-100, 1% BSA, and incubated for 2 h at 37°C. The plate was washed with PBS, 0.05% Tween 20. The presence of the polyclonal antibody was detected with goat anti-rabbit immunoglobulins conjugated with horseradish peroxidase. This antibody conjugate had been previously incubated with the monoclonal antibody WPI to minimize the background. The conjugate was detected with 0.1 mg/ml 3,3 ',5,5 '-tetramethylbenzidine, 0.0036% H202 in 0.1 M NaHCOOH pH 5.5 and quantified using a EASIA reader, (Medgenix Diagnostics BV, Soesterberg, The Netherlands). The amount of UGT1 present in the samples was calculated by constructing a standard curve from the titration of the isolated human UGT and fitting this curve with the softmax program, supplied with the EASIA reader.
Assay of B-UGT activity
DOPC liposomes were prepared in 10 mM Hepes pH 7.8, 150 mM NaCl, by sonication (19) , centrifuged at 4000 g for 10 min to remove titanium particles, stored at 4°C under argon, and used within 2 wk.
Human liver microsomes or COS cell microsomes (100-300 Mg protein) were incubated with DOPC liposomes for 30 min at 4°C before the assay. Concentrations in the reaction mixture were 50 mM Tris HCl pH 7.8, 5 mM MgCl2, 3.5 mM UDPGA, 1 mM 1,4 saccharolactone, 2.5 mg/ml DOPC SUV, and 2.5-75 MuM bilirubin in a total volume of 400 Ml. Incubations were performed under argon in the dark at 37°C for 10 min up to 4 h. All manipulations with bilirubin were performed in the dark or under dimmed light. Bilirubin solutions were prepared as follows: 2.9 mg of bilirubin was dissolved in 1.25 ml 50 mM NaOH by vortexing until the solution was optically clear, and neutralized by the addition of 3.75 ml of 100 mM Tris HCl pH 7.8. Bilirubin solutions were used within 5 min after preparation. For the determination of initial rates of bilirubin glucuronide formation a concentration range of 2.5-40 juM bilirubin was used. Maximal 15% of bilirubin was glucuronidated at the lowest concentrations of bilirubin employed. Reactions were stopped and bilirubin and conjugates were extracted by a modification of an existing procedure [20] . First a dash of ascorbic acid was added to the reaction vessels, subsequently 1.4 ml of chloroform/ethanol 1:1 (vol/ vol) and I ml of 0.4 M HCl adjusted to pH 1.8 with solid glycine was added and the mixture was vortexed vigorously. The tubes were centrifuged at 3000 rpm for 5 min. The lower colored phase was aspirated and transferred to a glass tube. The chloroform was immediately evaporated under a stream of nitrogen. Samples were stored under argon in the dark at -20°C for up to 2 d. The time needed from extraction to storage was less than 30 min. The percentage of bilirubin conjugated was determined using reverse phase HPLC (21). Bilirubin and bilirubin conjugates were dissolved in 100 MI chloroform/ethanol 1:1 (vol/vol), 20 M1 was injected onto a HPLC system equipped with a chromsep C18 column within 5 min after dissolving. Elution was monitored at 450 nm using a diode array detector; to confirm the identity of the peaks spectra were examined. The percentage of bilirubin conjugated was calculated by determining the integrated peak areas.
Calculation of kinetic parameters
The contribution of diglucuronides to the total amount of glucuronides was highest at low bilirubin concentrations but never exceeded 10%. Since B-UGT has the same affinity for unconjugated bilirubin as for monoglucuronide and since both are competitors for the same binding site (22) , diglucuronides were treated as two monoglucuronides.
Substrate concentration and the initial rates of glucuronide formation were fitted directly to the Michaelis-Menten equation using the 1 site ligand binding curve fitting option in slide write plus 5.0 to obtain the kinetic parameters.
Protein electrophoresis and Western blotting SDS PAGE was performed according to (23) on a Hoeffer Scientific instruments Mighty Small II system. Western blotting of the separated proteins on a nitrocellulose membrane was carried out in a electroblotting apparatus. UGT was visualized with mouse ascites containing the monoclonal antibody WP1 (18) or a polyclonal serum, 6215. Goat antirabbit or mouse immunoglobulins conjugated with alkaline phosphatase were used as secondary antibodies. The presence of the conjugate was detected with 0.33 mg/ml nitro blue tetrazolium and 0.17 mg/ml 5bromo-4-chloro-3-indoyl phosphate in 100 mM Tris pH 9.5, 100 mM NaCl, and 5 mM MgCl.
Protein was determined with fluorescamine (24) using bovine serum albumin as a standard. with the mutations described in Table I were expressed in COS cells. Microsomal fractions of the cells were subjected to SDS PAGE and Western blotting. UGT was detected using a polyclonal serum raised against human UGT. In Fig. 1 a Western blot is shown with the expressed proteins used for this study. The recombinant proteins appear identical, they have the same electrophoretic mobility and no signs of degradation are seen.
Results
To investigate whether the UGT antibodies available to us were suitable to develop a quantitative sandwich ELISA, we subjected two identical gels to Western blotting with two different antibodies. This is shown in Fig. 2 . B-UGT was visualized with the monoclonal antibody WPI, which is directed against the common region of all UGTI encoded enzymes and with a polyclonal antibody raised against immunopurified human UGT ( 1 8).
Human liver microsomes contain two immunoreactive UGTs with apparent molecular masses of 51 and 55 kD, COS cells transfected with wild type or recombinant B-UGT1 cDNA contain only one immunoreactive protein. COS cells transfected with the lac Z gene show no immunoreactivity at all. The bands of the recombinant proteins with the type II mutations appear somewhat fuzzy, probably because more protein was applied in these lanes. Western blots with the monoclonal and polyclonal antibody essentially show the same pattern. We concluded that both antibodies reacted with wild type and recombinant proteins and could be used to develop a quantitative ELISA. The monoclonal antibody was used to coat microtiter plates. UGT is a membrane protein and had to be solubilized with 1% Triton X-100 before binding to the antibody-coated plate could take place. To prevent reconstitution during dilution of UGT 0.1% Triton X-100 was included in the dilution buffer. A preparation of immunopurified UGT (16) processed in the same way as the microsomal samples from the COS cells was used as a standard. The polyclonal antibody was used to detect UGT that bound to the immobilized monoclonal antibody. Fig. 3 shows the titration of immunopurified standard UGT and microsomes from-COS cells transfected with normal or recombinant UGT cDNA. As a control titration of COS cells transfected with the lac Z gene is shown. The titration curves have the same slope, indicating that the binding affinity of the antibodies is not affected by the mutations. This sandwich ELISA was used to quantitate the amount of UGT that was present in the transfected COS cells.
Quantitation of B-UGT activity. Bilirubin is poorly soluble in water but readily dissolves in membranes (25) . It also associates rapidly with preformed liposomes (26, 27) . The bilirubin liposome complex is a good substrate for B-UGT (28) . Furthermore, dioleoyl phosphatidylcholine (DOPC) is a good activator of UGT (29) , therefore a high concentration of DOPC liposomes was used in our assay system, this served not only to activate B-UGT but also enabled us to accurately measure enzyme activity at concentrations at which bilirubin is not soluble in water. B-UGT activity was measured by HPLC and the amount of B-UGT polypeptide present in the fractions used for the B-UGT assay was measured by sandwich ELISA. In this way the specific activities of the expressed B-UGTs could be calculated.
The following control experiments were performed, prolonged incubations with microsomes from untreated COS cells and from COS cells transfected with the Escherichia coli p galactosidase gene and incubations with COS cell microsomes transfected with normal and mutant B-UGT without UDPglucuronate. In all these cases no bilirubin mono-or diglucuronide peaks were seen in the HPLC chromatograms.
When B-UGT2 cDNA was expressed in COS cells, enzyme was produced which had less than 0.1% activity when compared to expressed B-UGT1. All B-UGTI cDNAs from type I patients expressed in COS cells yielded inactive enzyme. Even after prolonged incubation times, up to 4 h, no activity was detectable. We did not express cDNAs which would give rise to truncated proteins.
With B-UGT1 cDNA from type II patients, enzyme was produced with partial activity. At a substrate concentration of 75 ,uM bilirubin, cDNA derived from patient A was found to encode for an enzyme with 4.4+2% residual activity and cDNA from patient B for an enzyme with 38+2% residual activity. These percentages are expressed relative to the specific activity of the wild type enzyme. In Table II the specific activities of wild type and mutated, type II B-UGTls are summarized. Values for the specific activities are mean+SD from three separate experiments.
Although patient B has only one functional allele, the high residual activity can not explain the elevated serum bilirubin levels observed in this patient. To investigate this further we determined the affinity of normal and mutant protein for bilirubin by measuring the activity at different substrate concentrations. The results are depicted in Table III . Values were obtained from three separate experiments. Double reciprocal plots of initial rates of glucuronide formation (1/V) versus bilirubin concentration (1/S) from a representative experiment are shown in Fig. 4 . Kinetic parameters of expressed normal B-UGT1 and human liver microsomes are virtually identical. The observed Km values agree with previously published data (Km = 13.7 I.M) although assay conditions and detection method employed were different (22) . The mutation from patient B causes a 10-fold increase in the apparent Km for bilirubin when compared to expressed B-UGTI or human liver microsomes. Microsomal fractions were incubated with different bilirubin concentrations and the initial rates of bilirubin glucuronide formation were determined using HPLC. These data were fitted to the Michaelis-Menten equation and the Vma,, and Km were calculated. Data represent means±SD from three separate experients. ND, not done.
Interestingly this mutation causes only a small alteration in the
Vm.x, an indication that only the binding of bilirubin is affected.
Thus, at a physiological concentration of bilirubin, this type II patient will have a markedly reduced ability to glucuronidate bilirubin, whereas a significant level of residual activity is observed at the relatively high bilirubin concentration used in the in vitro assay.
Discussion
Crigler-Najjar disease can be divided in two subtypes, type I and II. The discrimination between these types is based upon the following clinical criteria: in type II, phenobarbital treatment lowers serum bilirubin levels with more than 30% and bilirubin glucuronides are present in bile. Type I patients do not respond to phenobarbital treatment and only traces of bilirubin glucuronides can be found in their bile (2) . Analysis of liver material from biopsies or tissue removed during transplantation has revealed that in type I liver no B-UGT activity is present, whereas in type II liver sometimes a small residual activity can be observed (2) (3) (4) (5) (6) (7) (8) (9) (10) . Until now it was not clear which enzyme was responsible for this activity. Some heterogeneity in the clinical manifestation of CN type II is observed (2) (3) (4) (5) (6) (7) (8) (9) (10) . Phenobarbital response varies between 27 and 78% and serum bilirubin levels can vary between 340 and 100 1iM. The similarity between all type II patients is that symptoms are less severe than in type I and that usually no treatment is needed. However, patients have been described who could not be classified by the existing criteria, CN type II patients with bilirubin-induced neurological damage have been reported (30, 31) and a patient has been described who could not be classified at all (32) .
The cloning and characterization of the UGTI gene has led to the discovery of a rapidly accumulating array of mutations present in the B-UGTI gene of patients with the CN syndrome (13-15, 33, 34) . The role these different point mutations might play in the development of the subtypes of the CN syndrome has not been investigated so far.
In this study we examined several CN type I and II patients and identified the mutations present in the B-UGTI gene of these patients. Subsequently the effect these mutations have on the specific B-UGT enzyme activity was determined.
When cDNAs from the CN type I patients described in this study were transfected in COS cells, inactive B-UGTs were produced. Patient A, diagnosed as CN type II, has a B-UGTI gene that gave rise to an enzyme with 4.4% residual activity, serum bilirubin levels are elevated to 340 .tM, but the patient is currently without any treatment. Patient B, also diagnosed as type II, has a B-UGTI gene that gave rise to an enzyme with reduced activity as well. The reduction of B-UGT activity in this patient was caused by a 10-fold decreased affinity for bilirubin of B-UGTI. This will result in an approximately ten-fold reduction in the glucuronidation capacity at physiological bilirubin concentrations well below the Km. At high concentrations of bilirubin, B-UGT activity will approach a normal value. This may explain why the serum bilirubin level is relatively low in this patient. With only limited treatment serum bilirubin levels are elevated to a value of only 100-130 ttM.
Several lines of evidence argue against a role of B-UGT2 in the development of CN syndrome. The common carboxy terminal regions of both B-UGTI and B-UGT2 are derived from the four shared exons at the 3' region of the UGTI gene. As a consequence, mutations in any one of these exons will be present in both B-UGT isoforms. In this study such a mutation was found in patient D. When a mutation is present in the unique exon encoding the NH2 terminal region of B-UGT1 (UGTIA), B-UGT2 mRNA is not affected. This is the case in patients F, G, and H. Nevertheless B-UGT activity was absent in liver material of all these patients, suggesting that B-UGT2 does not contribute significantly to bilirubin conjugation in these patients. Furthermore we have shown that the specific activity of B-UGT2 is less than 0.1% of the activity of B-UGTI (35) . It is also known that B-UGT2 mRNA is expressed at a lower level than B-UGTl mRNA (11) . Together these arguments strongly suggest that B-UGTl accounts for practically all bilirubin glucuronidating activity in human liver (35) .
These data give rise to the following model: the development of CN disease is entirely govemed by the presence of mutations in the B-UGTI gene. Mutations in the constant or variable region that give rise to inactive enzymes result in CN type I. When the enzyme is only partially inactivated CN type II is developed.
Expression of Mutant Bilirubin UDP-Glucuronosyltransferase
The mechanism by which phenobarbital reduces serum bilirubin of CN type II patients is complex, probably more than one pathway is involved. In the Gunn rat, which has no B-UGT activity because it synthesizes a truncated enzyme (36) and which is an animal model for CN type I, phenobarbital treatment reduces serum bilirubin by 36% (37) . In CN type I patients a small reduction of serum bilirubin upon phenobarbital treatment is sometimes also seen (4). The reduction of serum bilirubin after phenobarbital treatment in Gunn rats has been explained by a mobilization of bilirubin to the liver probably caused by the induction of cytosolic binding proteins such as ligandin (37) . In type I patients similar mechanisms might play a role.
Although B-UGTl (UGTIA) mRNA is not induced by phenobarbital in monkeys (38) , studies with human liver (39, 40) and studies with the human hepatoma HEPG2 (41 ) suggest that both B-UGT transcription and B-UGT activity are increased after phenobarbital treatment. Other factors such as alteration of the membrane environment or a stabilization of microsomal protein (42) might also play a role in the phenobarbital induced induction of B-UGT activity. The reduction of serum bilirubin levels after phenobarbital treatment observed in type II patients may thus be attributed to the induction of the mutated B-UGT1, which has enzyme activity, albeit at a reduced level.
Patients with residual B-UGTI activity, CN type II, will benefit from mechanisms which increase B-UGT activity, whereas reduction of serum bilirubin in type I patients may be caused by the aspecific processes described above. The response a given CN patient, either type I or II, will have to phenobarbital treatment will depend on the way the different pathways are already induced.
The discrimination between type I and II CN should, in our opinion, be based on the presence of residual B-UGTl activity in type II patients and the absence of activity in type I patients. This differentiation is clinically important for prognostication and for prediction of the need for liver transplantation. Our studies demonstrate that this differentiation can now be made by the identification of the mutations in B-UGTI and the in vitro expression of the mutagenized B-UGT1.
In other inherited syndromes, such as lysosomal storage diseases, variability in clinical symptoms can also be understood as the consequence of differences in the residual activity of the affected enzymes (43) .
The criterion of > 30% reduction of serum bilirubin after phenobarbital treatment for type II seems somewhat arbitrary. For the initial clinical diagnosis, however, it will remain an important tool.
